Search results for "BOCEPREVIR"

showing 10 items of 34 documents

Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?

2012

The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin resulted in a significant gain in terms of sustained virological response (SVR) when treating naive or previous treated patients with genotype 1 (G1) chronic hepatitis C (CHC). This gain is partly balanced by the increased complexity of treatment and by the raised costs and risks of therapy, making necessary to optimize the indication to TT. Specifically, the identification of patient needing to TT over DT, the choice of the more correct therapeutic approach according to baseline and on treatment SVR predictors, and the timing of…

Oncologymedicine.medical_specialtyReviewPharmacologyAntiviral AgentsTelaprevirVirological responsechemistry.chemical_compoundMedical microbiologyChronic hepatitisPegylated interferonInternal medicineBoceprevirmedicineHumansbusiness.industryRibavirinHepatitis C ChronicDAA HCVEconomic RecessionInfectious DiseaseschemistryPractice Guidelines as TopicDrug Therapy CombinationbusinessAlgorithmsmedicine.drug
researchProduct

Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO2…

2013

Pediatricsmedicine.medical_specialtyTotal costbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthTreatment failureTelaprevirchemistry.chemical_compoundchemistryBoceprevirmedicinebusinessmedicine.drugValue in Health
researchProduct

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2013

We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source. The target population was made up of untreated Caucasian patients, aged 50 years, with G1CHC and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euros at 2013 value), life-years gained (LYG), quality-adju…

Settore MED/12 - Gastroenterologiamedicine.medical_specialtyCirrhosisHepatologySofosbuvirCost effectivenessbusiness.industryGastroenterologyPharmacologyHepatologycost-effectiveness sofosbuvir boceprevir telaprevir chronic hepatitis Cmedicine.diseaseTelaprevirchemistry.chemical_compoundchemistryTolerabilityBoceprevirInternal medicineGenotypemedicineSettore SECS-S/05 - Statistica SocialeSettore SECS-S/01 - Statisticabusinesshealth care economics and organizationsmedicine.drugDigestive and Liver Disease
researchProduct

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1)…

2014

Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens have a high pill burden and are associated with increased rates and severity of adverse events, such as anaemia and rash. The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection.In QUEST-1, a phase 3, randomise…

SimeprevirAdultMalemedicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsDrug Administration ScheduleTelaprevirPolyethylene Glycolschemistry.chemical_compoundDouble-Blind MethodPegylated interferonSimeprevirBoceprevirInternal medicineRibavirinmedicineHumanschronic hepatitis CSulfonamidesbusiness.industryRibavirinvirus diseasesInterferon-alphaGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryDrug Therapy CombinationFemalebusinessHeterocyclic Compounds 3-Ringmedicine.drugPeginterferon alfa-2a
researchProduct

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women

2014

AIM: To investigate the safety/efficacy of Boceprevirbased triple therapy in hepatitis C virus (HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders. METHODS: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure (7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEGIFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-positive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virolo…

Time FactorsViral HepatitisClinical Trials StudyHepacivirusViral hepatitiPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundPegylated interferonOdds RatioMultivariate AnalysiPegylated InterferonGastroenterologyGeneral MedicineHepatitis CHepatitis c virus treatmentMiddle AgedRecombinant ProteinViral LoadGenotype 1Recombinant ProteinsMenopauseTreatment OutcomeItalyRNA ViralDrug Therapy CombinationFemaleMenopauseViral hepatitisViral loadPegylated interferonHumanmedicine.drugmedicine.medical_specialtyGenotypeLogistic ModelProlineTime FactorInterferon alpha-2Hepatitis C virus treatmentAntiviral AgentsPharmacotherapyInternal medicineBoceprevirRibavirinmental disordersmedicineHumansAntiviral AgentHepacivirubusiness.industryInterferon-alphaBiomarkerGenotype 1; Hepatitis c virus treatment; Menopause; Pegylated interferon; Viral hepatitis; Antiviral Agents; Biomarkers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Logistic Models; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; RNA Viral; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Menopause; GastroenterologyHepatitis C Chronicmedicine.diseaseVirologyLogistic ModelschemistryHepatitis C Virus PositiveMultivariate AnalysisGenotype 1; Hepatitis C virus treatment; Menopause; Pegylated Interferon; Viral HepatitisbusinessBiomarkers
researchProduct

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2014

We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source. The target population was made up of untreated Caucasian patients, aged 50 years, with G1CHC and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euros at 2013 value), life-years gained (LYG), quality-adju…

medicine.medical_specialtyCirrhosisHepatologySofosbuvirCost effectivenessbusiness.industryHepatologymedicine.diseaseSurgeryQuality-adjusted life yearTelaprevirchemistry.chemical_compoundTolerabilitychemistryBoceprevirInternal medicinemedicinebusinesshealth care economics and organizationsmedicine.drugHepatology
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation

2014

medicine.medical_specialtyKidneyHepatologyRe transplantationbusiness.industryGastroenterologyMEDLINEHepatitis Cmedicine.diseaseGastroenterologychemistry.chemical_compoundmedicine.anatomical_structurePharmacotherapychemistryInternal medicineBoceprevirmedicinebusinessViral loadKidney transplantationDigestive and Liver Disease
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct